Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy

References

• Hamilton B, Martin J, Ventura S. Births: Preliminary data for 2008. National Vital Statistics Reports 2010; 58:16. Available at http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_16.pdf. Accessed December 21, 2010
   Google Scholar
• Dezen T, Lynch E. Preterm birth rate drops three percent. 2010. Available at: http://www.marchofdimes.com/printableArticles/49267_63686.asp. Accessed November 9, 2010.
   Google Scholar
• Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75–84.
   PubMed Web of Science ®Google Scholar
• Iams JD. The epidemiology of preterm birth. Clin Perinatol 2003;30:651–664.
   PubMed Web of Science ®Google Scholar
• Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, Schwarz RH, Damus K. Estimated effect of 17 α-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005;105:267–272.
   PubMed Web of Science ®Google Scholar
• McManemy J, Cooke E, Amon E, Leet T. Recurrence risk for preterm delivery. Am J Obstet Gynecol 2007;196:576.e1–6; discussion 576.e6.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Vaccaro V. Pharmacological use of progesterone and 17-α-hydroxyprogesterone caproate in the prevention of preterm delivery. Minerva Ginecol 2009;61:401–409.
   PubMedGoogle Scholar
• Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, et al.; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 α-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–2385.
   PubMed Web of Science ®Google Scholar
• Meis PJ, Klebanoff M, Dombrowski MP, Sibai BM, Leindecker S, Moawad AH, Northen A, et al. Does progesterone treatment influence risk factors for recurrent preterm delivery? Obstet Gynecol 2005;106:557–561.
   PubMed Web of Science ®Google Scholar
• Tita AT, Rouse DJ. Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol 2009; March:219–224 doi: 10.1016/j.ajog.2008.12.035. Accessed May 7, 2010.
   Google Scholar
• Asrat T, Lewis DF, Garite TJ, Major CA, Nageotte MP, Towers CV, Montgomery DM, Dorchester WA. Rate of recurrence of preterm premature rupture of membranes in consecutive pregnancies. Am J Obstet Gynecol 1991;165:1111–1115.
   PubMed Web of Science ®Google Scholar
• Ekwo EE, Gosselink CA, Moawad A. Unfavorable outcome in penultimate pregnancy and premature rupture of membranes in successive pregnancy. Obstet Gynecol 1992;80:166–172.
   PubMed Web of Science ®Google Scholar
• Lee T, Carpenter MW, Heber WW, Silver HM. Preterm premature rupture of membranes: risks of recurrent complications in the next pregnancy among a population-based sample of gravid women. Am J Obstet Gynecol 2003;188:209–213.
   PubMed Web of Science ®Google Scholar
• Mercer BM, Goldenberg RL, Meis PJ, Moawad AH, Shellhaas C, Das A, Menard MK, et al. The Preterm Prediction Study: prediction of preterm premature rupture of membranes through clinical findings and ancillary testing. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 2000;183:738–745.
   PubMed Web of Science ®Google Scholar
• Shen TT, DeFranco EA, Stamilio DM, Chang JJ, Muglia, LJ. A population-based study of race-specific risk for preterm premature rupture of membranes. Am J Obstet Gynecol 2008; 199:373.e.1–373.e.7. doi:10.1016/j.ajog.2008.05.011. Accessed May 7, 2010.
   Web of Science ®Google Scholar
• O’Brien JM, Lewis DF. Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies. J Reprod Med 2009;54:73–87.
   PubMed Web of Science ®Google Scholar
• Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, Hauth JC, et al. National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol 2005;193:1127–1131.
   PubMed Web of Science ®Google Scholar
• González-Quintero VH, de la Torre L, Rhea DJ, Tudela CM, Vazquez-Vera E, Desch C, Istwan NB. Impact of prior gestational age at preterm delivery on effectiveness of 17-α-hydroxyprogesterone caproate in practice. Am J Obstet Gynecol 2010;203:257.e1–257.e5.
   Web of Science ®Google Scholar
• Mercer BM, Goldenberg RL, Moawad AH, Meis PJ, Iams JD, Das AF, Caritis SN, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999;181:1216–1221.
   PubMed Web of Science ®Google Scholar
• How HY, Barton JR, Istwan NB, Rhea DJ, Stanziano GJ. Prophylaxis with 17 α-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter? Am J Obstet Gynecol 2007;197:260.e1–260.e4.
   Web of Science ®Google Scholar
• Luo G, Abrahams VM, Tadesse S, Funai EF, Hodgson EJ, Gao J, Norwitz ER. Progesterone inhibits basal and TNF-α-induced apoptosis in fetal membranes: a novel mechanism to explain progesterone-mediated prevention of preterm birth. Reprod Sci 2010;17:532–539.
   PubMed Web of Science ®Google Scholar